Condition
High Risk Smoldering Multiple Myeloma
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Terminated1
Completed1
Recruiting1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06745687Not ApplicableNot Yet RecruitingPrimary
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NCT06574126Phase 2RecruitingPrimary
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
NCT02697383Phase 1Completed
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
NCT02943473Phase 2TerminatedPrimary
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Showing all 4 trials